PCVXVaxcyte, Inc.

$9B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$114M

Net Income

-$95M

EPS (Diluted)

$-0.85

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$159M

Free Cash Flow

-$171M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$107M

Stockholders' Equity

$2.0B

Cash & Equivalents

$612M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$114M	-$71M	-60.8%
Net Income	-$95M	-$60M	-57.2%

PCVX Q1 2024 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena